AI Science Tracker

Chai Discovery

1 discovery from 2025

Discoveries

Chai Discovery

Chai-2 reports 16% hit rate in zero-shot de novo antibody design

Source check: Needs source check. Not independent scientific confirmation.

Finding: Designing at most 20 antibodies or nanobodies per target for 52 targets without prior PDB binders gave at least one hit for 50% of targets in a single round; 68% wet-lab success for miniproteins. Preprint; the abstract is the only material reviewed; independent replication and developability are not shown; some strengths come from the company's own assays.

Technology: Chai-2 multimodal generative model

Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
Generative model proposed antibody/nanobody sequences tested in wet-lab binding assays.
Test and result
Designing at most 20 antibodies or nanobodies per target for 52 targets without prior PDB binders gave at least one hit for 50% of targets in a single round; 68% wet-lab success for miniproteins.
Limitation / still unknown
Preprint; the abstract is the only material reviewed; independent replication and developability are not shown; some strengths come from the company's own assays.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:%2210.1101/2025.07.05.663018%22&resultType=core&format=json

Needs source check · editorial details

The source has not been fully checked or contains conflicting information. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 17 Nov 2026. Review scope: Abstract and metadata via Europe PMC; full text not read.

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.